Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Compugen Ltd. (Nasdaq: CGEN) has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, with a fireside chat scheduled for September 5, 2025. This event highlights Compugen’s role as a clinical-stage cancer immunotherapy company leading in predictive computational target discovery, leveraging artificial intelligence and machine learning technologies.

The fireside chat will provide insights into Compugen's innovative approach and will be accessible on the company's Investor Relations page for 90 days post-event. Compugen is known for its Unigen™ platform, which aids in identifying novel drug targets and biological pathways critical for developing cancer treatments.

The company's product portfolio includes two proprietary candidates in Phase 1 development: COM701, an anti-PVRIG antibody positioned as a potential first-in-class treatment, and COM902, which targets TIGIT, aiming to become a best-in-class therapy for solid tumors. Additionally, Compugen is collaborating with AstraZeneca on rilvegostomig, a PD-1/TIGIT bispecific antibody derived from COM902, which is currently in Phase 3 development. Another candidate, GS-0321 (formerly COM503), is a high-affinity anti-IL-18 binding protein antibody in Phase 1 and is licensed to Gilead.

Compugen, headquartered in Israel with a presence in San Francisco, CA, is committed to advancing immuno-oncology through its early-stage research programs, which focus on new mechanisms to enhance the immune response against cancer. With its shares traded on both Nasdaq and the Tel Aviv Stock Exchange under CGEN, Compugen stands at the forefront of cancer therapeutic innovation.

For further inquiries, investors can contact Yvonne Naughton, Ph.D., the company’s Vice President of Investor Relations.

Compugen Ltd. (Nasdaq: CGEN) is set to present at the H.C. Wainwright 27th Annual Global Investment Conference, an opportunity that investors should closely monitor. As a clinical-stage cancer immunotherapy company leveraging advanced AI/ML technologies for drug discovery, Compugen is at the forefront of a rapidly evolving sector that could reshape treatment paradigms for cancer.

Currently, Compugen has two promising product candidates—COM701 and COM902—both in Phase 1 development, targeting critical pathways in immuno-oncology. COM701 is positioned as a potential first-in-class anti-PVRIG antibody, while COM902 aims to be a best-in-class TIGIT-targeting antibody. These compounds are aimed at treating solid tumors, where significant unmet needs persist. The backdrop of robust market demand for innovative cancer therapies suggests a favorable environment for companies like Compugen, particularly those at the leading edge of technological advancement.

Moreover, the ongoing development of Rilvegostomig, a bispecific antibody in Phase 3 trials by AstraZeneca, underscores the potential validation of Compugen's technology and pipeline. This collaboration not only enhances credibility but also potentially opens avenues for future monetization through royalties and licensing agreements.

Investors should take note of the upcoming fireside chat, available on-demand from September 5, 2025. This presentation will likely provide critical insights into Compugen's strategic direction, pipeline updates, and market position. Listening in could reveal potential catalysts that might impact share price and investor sentiment.

In conclusion, Compugen's innovative approach and advancing pipeline position it well within the high-growth immunotherapy market. For investors seeking exposure to the biotech sector, monitoring Compugen's developments and conference presentations could present insightful investment opportunities moving forward. The focus on AI/ML for drug discovery also indicates adherence to future industry trends that favor technology-enabled healthcare solutions.